Q-omics provides the consensus-scored TMEM63C profile across patient tissues and cancer cell-line models. TMEM63C expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, TMEM63C is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, TMEM63C RNA expression shows 20,000 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, COAD, and GBM as cancer lineages where TMEM63C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMEM63C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMEM63C survival associations across molecular data types. TMEM63C RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMEM63C RNA expression–survival associations across cancer types. High TMEM63C expression shows unfavorable associations in KIRC, UCEC and STAD, but favorable associations in LUAD, LGG and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for TMEM63C RNA expression.
This table summarizes TMEM63C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TMEM63C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMEM63C shows lower tumor expression in COAD and KIRC and higher tumor expression in LUAD, BRCA, HNSC and LUSC. The COAD box plot shows higher TMEM63C RNA expression in normal versus tumor tissue (log2 FC = −1.350, t-test p < 0.001).
This table shows molecular features associated with TMEM63C in patient tissues and cancer cell lines. In patient samples, TMEM63C shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TMEM63C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in CNS and BREAST.
